The adult trial is interesting comparing Rem-L against SOC (we know who that is ... lol)
The other interesting comment about the adult GVHD rollout (assuming it passes or is better than SOC) is going to be handled internally by Mesoblast - no partner ? That will make a big difference to revenues not having to share revenues in this indication.
Ann: MSB Annual Financial Results and Operational Progress, page-16
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
95.0¢ |
Change
-0.005(0.52%) |
Mkt cap ! $1.084B | |||
| Open | High | Low | Value | Volume |
| 96.0¢ | 98.5¢ | 91.5¢ | $4.743M | 4.999M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 123302 | 95.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 95.5¢ | 314 | 1 |
View Market Depth
| Last trade - 16.10pm 29/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |